← Eichor
Condition: Secondary Progressive Multiple Sclerosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Secondary Progressive Multiple Sclerosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Phase N/A · 1 location(s) · Shirley Ryan AbilityLab · NCT06516458A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Fo
Phase 1 · 1 location(s) · Stanford University · NCT06138132Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Phase 3 · 22 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT04047628"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Phase N/A · 1 location(s) · University of California, San Francisco · NCT07222618Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
NA · 1 location(s) · Shirley Ryan AbilityLab · NCT06390930Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT05177523MS-ResearchBiomarkerS
Phase N/A · 1 location(s) · Cedars-Sinai Medical Center · NCT05204459A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Phase 3 · 236 location(s) · Novartis Pharmaceuticals · NCT07225504Intermittent Hypoxia in Persons With Multiple Sclerosis
NA · 1 location(s) · Shirley Ryan AbilityLab · NCT06276634A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1 · 8 location(s) · TG Therapeutics, Inc. · NCT06680037Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Phase 1/Phase 2 · 2 location(s) · Tr1X, Inc. · NCT07477639The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Phase 2 · 1 location(s) · Cairo University · NCT06599307Home Based Functional Balance Intervention for Multiple Sclerosis
NA · 1 location(s) · University of Illinois at Chicago · NCT07355387Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Phase 2/Phase 3 · 1 location(s) · Institute of Psychiatry and Neurology, Warsaw · NCT05961644Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Phase N/A · 2 location(s) · Heinrich-Heine University, Duesseldorf · NCT07426991Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Phase 1 · 1 location(s) · Queen Mary University of London · NCT03783416A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Phase 3 · 20 location(s) · Zenas BioPharma (USA), LLC · NCT07299019Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT06526364Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Phase 2 · 1 location(s) · Tiziana Life Sciences LTD · NCT06890923
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.